1. Home
  2. MELI vs REGN Comparison

MELI vs REGN Comparison

Compare MELI & REGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo MercadoLibre Inc.

MELI

MercadoLibre Inc.

HOLD

Current Price

$1,545.67

Market Cap

94.0B

ML Signal

HOLD

Logo Regeneron Pharmaceuticals Inc.

REGN

Regeneron Pharmaceuticals Inc.

HOLD

Current Price

$703.72

Market Cap

77.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MELI
REGN
Founded
1999
1988
Country
Uruguay
United States
Employees
N/A
N/A
Industry
Catalog/Specialty Distribution
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
94.0B
77.5B
IPO Year
2007
1995

Fundamental Metrics

Financial Performance
Metric
MELI
REGN
Price
$1,545.67
$703.72
Analyst Decision
Strong Buy
Buy
Analyst Count
17
25
Target Price
$2,666.47
$830.16
AVG Volume (30 Days)
441.4K
667.2K
Earning Date
05-04-2026
04-29-2026
Dividend Yield
N/A
0.55%
EPS Growth
4.54
8.19
EPS
8.23
6.75
Revenue
$28,893,000,000.00
$5,872,227,000.00
Revenue This Year
$36.23
$12.45
Revenue Next Year
$24.20
$10.13
P/E Ratio
$41.40
$105.71
Revenue Growth
39.06
20.82
52 Week Low
$1,593.21
$476.49
52 Week High
$2,645.22
$821.11

Technical Indicators

Market Signals
Indicator
MELI
REGN
Relative Strength Index (RSI) 29.71 40.58
Support Level N/A $679.36
Resistance Level $2,498.41 $783.87
Average True Range (ATR) 55.03 19.63
MACD -26.26 -1.64
Stochastic Oscillator 0.99 35.02

Price Performance

Historical Comparison
MELI
REGN

About MELI MercadoLibre Inc.

MercadoLibre is the largest e-commerce marketplace in Latin America, with more than 120 million unique active buyers and 1 million active sellers at the end of 2025. The company is roughly split between its e-commerce business, which includes its fulfillment and advertising services, and its fintech segment, which comprises its rapidly expanding payment and digital wallet platform (Mercado Pago) and its lending business (Mercado Credito). While the company operates in 18 countries, its primary markets are Brazil, Argentina, and Mexico, which account for more than 95% of its revenue.

About REGN Regeneron Pharmaceuticals Inc.

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has early-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).

Share on Social Networks: